Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 586-592, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcovina, S. M.
Right arrow Articles by Hannon, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcovina, S. M.
Right arrow Articles by Hannon, W. H.

Clinical Chemistry, Vol 40, 586-592, Copyright © 1994 by American Association for Clinical Chemistry

International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material

SM Marcovina, JJ Albers, H Kennedy, JV Mei, LO Henderson and WH Hannon
Department of Medicine, Northwest Lipid Research Laboratories, University of Washington, Seattle 98103.

We performed temporal and thermal stability studies on SP3-07, a liquid- stabilized reference material for apolipoprotein (apo) B, selected during the previous phase of the International Federation of Clinical Chemistry project on standardization of apolipoprotein measurements. Results indicate that SP3-07 stored at -70 degrees C has the long-term stability required for a reference material. We assigned an accuracy- based apo B value of 1.22 g/L to SP3-07, using a nephelometric method that was calibrated with freshly isolated low-density lipoprotein for which the apo B mass value was determined by a standardized sodium dodecyl sulfate-Lowry procedure. Using a common protocol, the study participants transferred the assigned mass value from SP3-07 to the individual calibrators of the analytical systems and measured the apo B concentration of 20 fresh-frozen samples obtained from individual donors and covering a clinically relevant range of apo B values. The among-laboratory CV on these samples, analyzed by 25 analytical systems, ranged from 3.1% to 6.7%. These results demonstrate the lack of matrix effects of SP3-07 and its ability to provide accurate and comparable apo B values in a variety of immunochemical methods. On the basis of the outcome of these studies, the World Health Organization has endorsed SP3-07 as the International Reference Material for Apolipoprotein B.


The following articles in journals at HighWire Press have cited this article:


Home page
 Eur J Heart FailHome page
I. Holme, A. H. Aastveit, N. Hammar, I. Jungner, and G. Walldius
Lipoprotein components and risk of congestive heart failure in 84 740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS)
Eur J Heart Fail, November 1, 2009; 11(11): 1036 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
E. Paz-Pacheco, M. A. Lim-Abrahan, R. A. G. Sy, G. V. Jasul, C. M. C. Sison, and A. F. Laurel
Adiponectin levels and its association with hyperglycaemia in adult Filipino participants in the 2003--04 National Nutrition and Health Survey
Diabetes and Vascular Disease Research, October 1, 2009; 6(4): 231 - 237.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
S. Parish, R. Peto, A. Palmer, R. Clarke, S. Lewington, A. Offer, G. Whitlock, S. Clark, L. Youngman, P. Sleight, et al.
The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls
Eur. Heart J., September 1, 2009; 30(17): 2137 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. S. Martin, A. N. Qasim, N. N. Mehta, M. Wolfe, K. Terembula, S. Schwartz, N. Iqbal, M. Schutta, R. Bagheri, and M. P. Reilly
Apolipoprotein B but not LDL Cholesterol Is Associated With Coronary Artery Calcification in Type 2 Diabetic Whites
Diabetes, August 1, 2009; 58(8): 1887 - 1892.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. H. Contois, J. P. McConnell, A. A. Sethi, G. Csako, S. Devaraj, D. M. Hoefner, and G. R. Warnick
Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
Clin. Chem., March 1, 2009; 55(3): 407 - 419.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. J.P. Kastelein, W. A. van der Steeg, I. Holme, M. Gaffney, N. B. Cater, P. Barter, P. Deedwania, A. G. Olsson, S. M. Boekholdt, D. A. Demicco, et al.
Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
Circulation, June 10, 2008; 117(23): 3002 - 3009.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. M. Baca and G. R. Warnick
Estimation of LDL-Associated Apolipoprotein B from Measurements of Triglycerides and Total Apolipoprotein B
Clin. Chem., May 1, 2008; 54(5): 907 - 910.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1512 - 1524.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Diabetes Care, April 1, 2008; 31(4): 811 - 822.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. J. Albers, S. M. Marcovina, G. Imperatore, B. M. Snively, J. Stafford, W. Y. Fujimoto, E. J. Mayer-Davis, D. B. Petitti, C. Pihoker, L. Dolan, et al.
Prevalence and Determinants of Elevated Apolipoprotein B and Dense Low-Density Lipoprotein in Youths with Type 1 and Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 735 - 742.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. O. Mudd, B. A. Borlaug, P. V. Johnston, B. G. Kral, R. Rouf, R. S. Blumenthal, and P. O. Kwiterovich Jr
Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease
J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1735 - 1741.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
E. Ingelsson, E. J. Schaefer, J. H. Contois, J. R. McNamara, L. Sullivan, M. J. Keyes, M. J. Pencina, C. Schoonmaker, P. W. F. Wilson, R. B. D'Agostino, et al.
Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women
JAMA, August 15, 2007; 298(7): 776 - 785.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
W. A. van der Steeg, S. M. Boekholdt, E. A. Stein, K. El-Harchaoui, E. S.G. Stroes, M. S. Sandhu, N. J. Wareham, J. W. Jukema, R. Luben, A. H. Zwinderman, et al.
Role of the Apolipoprotein B-Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case-Control Analysis in EPIC-Norfolk
Ann Intern Med, May 1, 2007; 146(9): 640 - 648.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
T. McLaughlin, S. Carter, C. Lamendola, F. Abbasi, G. Yee, P. Schaaf, M. Basina, and G. Reaven
Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults.
Am. J. Clinical Nutrition, October 1, 2006; 84(4): 813 - 821.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. S. Vasan
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Circulation, May 16, 2006; 113(19): 2335 - 2362.
[Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J. Q. Purnell, L. B. Bland, M. Garzotto, D. Lemmon, E. M. Wersinger, C. W. Ryan, J. D. Brunzell, and T. M. Beer
Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer
J. Lipid Res., February 1, 2006; 47(2): 349 - 355.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. D. Sniderman
Apolipoprotein B Versus Non-High-Density Lipoprotein Cholesterol: And the Winner Is...
Circulation, November 29, 2005; 112(22): 3366 - 3367.
[Full Text] [PDF]

Home page
 CirculationHome page
M. A. Denke
Weighing in Before the Fight: Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Versus Apolipoprotein B as the Best Predictor for Coronary Heart Disease and the Best Measure of Therapy
Circulation, November 29, 2005; 112(22): 3368 - 3370.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
A. M. Wagner, A. Perez, J. L. Sanchez-Quesada, and J. Ordonez-Llanos
Triglyceride-to-HDL Cholesterol Ratio in the Dyslipidemic Classification of Type 2 Diabetes
Diabetes Care, July 1, 2005; 28(7): 1798 - 1800.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. J. Blom, F. H. O'Neill, and A. D. Marais
Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations
Clin. Chem., May 1, 2005; 51(5): 904 - 907.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
C. Meisinger, H. Loewel, W. Mraz, and W. Koenig
Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study
Eur. Heart J., February 1, 2005; 26(3): 271 - 278.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Rifai, G. R. Cooper, W. V. Brown, W. Friedewald, R. J. Havel, G. L. Myers, and G. R. Warnick
Clinical Chemistry Journal Has Contributed to Progress in Lipid and Lipoprotein Testing for Fifty Years
Clin. Chem., October 1, 2004; 50(10): 1861 - 1870.
[Full Text] [PDF]

Home page
 CirculationHome page
M. J. Veerkamp, J. de Graaf, J. C.M. Hendriks, P. N.M. Demacker, and A. F.H. Stalenhoef
Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a 5-Year Follow-Up Study
Circulation, June 22, 2004; 109(24): 2980 - 2985.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Carmena, P. Duriez, and J.-C. Fruchart
Atherogenic Lipoprotein Particles in Atherosclerosis
Circulation, June 15, 2004; 109(23_suppl_1): III-2 - III-7.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
M. Averina, O. Nilssen, T. Brenn, J. Brox, V. L. Arkhipovsky, and A. G. Kalinin
Factors behind the Increase in Cardiovascular Mortality in Russia: Apolipoprotein AI and B Distribution in the Arkhangelsk Study 2000
Clin. Chem., February 1, 2004; 50(2): 346 - 354.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Snehalatha, B. Mukesh, M. Simon, V. Viswanathan, S. M. Haffner, and A. Ramachandran
Plasma Adiponectin Is an Independent Predictor of Type 2 Diabetes in Asian Indians
Diabetes Care, December 1, 2003; 26(12): 3226 - 3229.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. A. Austin, K. L. Edwards, S. A. Monks, K. M. Koprowicz, J. D. Brunzell, A. G. Motulsky, M. C. Mahaney, and J. E. Hixson
Genome-wide scan for quantitative trait loci influencing LDL size and plasma triglyceride in familial hypertriglyceridemia
J. Lipid Res., November 1, 2003; 44(11): 2161 - 2168.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. H. Knopp, B. Retzlaff, B. Fish, C. Walden, S. Wallick, M. Anderson, K. Aikawa, and S. E. Kahn
Effects of Insulin Resistance and Obesity on Lipoproteins and Sensitivity to Egg Feeding
Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1437 - 1443.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Wagner, O. Jorba, R. Bonet, J. Ordonez-Llanos, and A. Perez
Efficacy of Atorvastatin and Gemfibrozil, Alone and in Low Dose Combination, in the Treatment of Diabetic Dyslipidemia
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3212 - 3217.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. D. Sniderman
Non-HDL Cholesterol Versus Apolipoprotein B in Diabetic Dyslipoproteinemia: Alternatives and surrogates versus the real thing
Diabetes Care, July 1, 2003; 26(7): 2207 - 2208.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
C.J. Packard
Apolipoproteins: the new prognostic indicator?
Eur. Heart J. Suppl., June 1, 2003; 5(suppl_D): D9 - D16.
[Abstract] [PDF]

Home page
 DiabetesHome page
D. J. Nieves, M. Cnop, B. Retzlaff, C. E. Walden, J. D. Brunzell, R. H. Knopp, and S. E. Kahn
The Atherogenic Lipoprotein Profile Associated With Obesity and Insulin Resistance Is Largely Attributable to Intra-Abdominal Fat
Diabetes, January 1, 2003; 52(1): 172 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Miremadi, A. Sniderman, and J. Frohlich
Can Measurement of Serum Apolipoprotein B Replace the Lipid Profile Monitoring of Patients with Lipoprotein Disorders?
Clin. Chem., March 1, 2002; 48(3): 484 - 488.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall
Risk factors for coronary heart disease: implications of gender
Cardiovasc Res, February 15, 2002; 53(3): 538 - 549.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. R. Tannock, K. L. Olin, P. H. R. Barrett, T. N. Wight, and A. Chait
Triglyceride-Rich Lipoproteins from Subjects with Type 2 Diabetes Do Not Demonstrate Increased Binding to Biglycan, a Vascular Proteoglycan
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 35 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. Frohlich, A. Sniderman, and R. H. Eckel
Familial Combined Hyperlipidemia and Insulin Resistance
Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 2100 - 2101.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
A. D. Sniderman, T. Scantlebury, and K. Cianflone
Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus
Ann Intern Med, September 18, 2001; 135(6): 447 - 459.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
A. D. Sniderman, J. Bergeron, and J. Frohlich
Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial
Can. Med. Assoc. J., January 1, 2001; 164(1): 44 - 47.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. M. Marcovina, J. J. Albers, A. M. Scanu, H. Kennedy, F. Giaculli, K. Berg, R. Couderc, F. Dati, N. Rifai, I. Sakurabayashi, et al.
Use of a Reference Material Proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to Evaluate Analytical Methods for the Determination of Plasma Lipoprotein(a)
Clin. Chem., December 1, 2000; 46(12): 1956 - 1967.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. M. Wagner, J. L. Sanchez-Quesada, A. Perez, M. Rigla, M. Cortes, F. Blanco-Vaca, and J. Ordonez-Llanos
Inaccuracy of Calculated LDL-Cholesterol in Type 2 Diabetes: Consequences for Patient Risk Classification and Therapeutic Decisions
Clin. Chem., November 1, 2000; 46(11): 1830 - 1832.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
J. R. Guyton, M. A. Blazing, J. Hagar, M. L. Kashyap, R. H. Knopp, J. M. McKenney, D. T. Nash, S. D. Nash, and for the Niaspan-Gemfibrozil Study Group
Extended-Release Niacin vs Gemfibrozil for the Treatment of Low Levels of High-Density Lipoprotein Cholesterol
Arch Intern Med, April 24, 2000; 160(8): 1177 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Lavrencic, B. G. Salobir, and I. Keber
Physical Training Improves Flow-Mediated Dilation in Patients With the Polymetabolic Syndrome
Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 551 - 555.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
N. Emanuele, N. Azad, C. Abraira, W. Henderson, J. Colwell, S. Levin, F. Nuttall, J. Comstock, C. Sawin, C. Silbert, et al.
Effect of Intensive Glycemic Control on Fibrinogen, Lipids, and Lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus
Arch Intern Med, December 1, 1998; 158(22): 2485 - 2490.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
I. Jungner, S. M. Marcovina, G. Walldius, I. Holme, W. Kolar, and E. Steiner
Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization–International Federation of Clinical Chemistry First International Reference Materials
Clin. Chem., August 1, 1998; 44(8): 1641 - 1649.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. Q. Purnell, J. E. Hokanson, S. M. Marcovina, M. W. Steffes, P. A. Cleary, and J. D. Brunzell
Effect of Excessive Weight Gain With Intensive Therapy of Type 1 Diabetes on Lipid Levels and Blood Pressure: Results From the DCCT
JAMA, July 8, 1998; 280(2): 140 - 146.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. A. Sanan, D. L. Newland, R. Tao, S. Marcovina, J. Wang, V. Mooser, R. E. Hammer, and H. H. Hobbs
Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: No accentuation by apolipoprotein(a)
PNAS, April 14, 1998; 95(8): 4544 - 4549.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. A. Espeland, S. M. Marcovina, V. Miller, P. D. Wood, C. Wasilauskas, R. Sherwin, H. Schrott, and T. L. Bush
Effect of Postmenopausal Hormone Therapy on Lipoprotein(a) Concentration
Circulation, March 17, 1998; 97(10): 979 - 986.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. S. Graziani, L. Zanolla, G. Righetti, C. Marchetti, P. Mocarelli, and S. M. Marcovina
Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group
Clin. Chem., January 1, 1998; 44(1): 134 - 140.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. R. McNamara, E. T. Leary, F. Ceriotti, C. M. Boersma-Cobbaert, T. G. Cole, D. J. Hassemer, M. Nakamura, C. J. Packard, D. W. Seccombe, M. M. Kimberly, et al.
Point Status of lipid and lipoprotein standardization
Clin. Chem., August 1, 1997; 43(8): 1306 - 1310.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. D. Sniderman
Counterpoint To (measure apo)B or not to (measure apo)B: a critique of modern medical decision-making
Clin. Chem., August 1, 1997; 43(8): 1310 - 1314.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
T. Planella, M. Cortes, C. Martinez-Bru, F. Gonzalez-Sastre, and J. Ordonez-Llanos
Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia
Clin. Chem., May 1, 1997; 43(5): 808 - 815.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. K. Parsons, S. X. Skapek, E. J. Neufeld, C. Kuhlman, M. L. Young, M. Donnelly, J. D. Brunzell, J. D. Otvos, S. E. Sallan, and N. Rifai
Asparaginase-Associated Lipid Abnormalities in Children With Acute Lymphoblastic Leukemia
Blood, March 15, 1997; 89(6): 1886 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. Lamarche, S. Moorjani, P. J. Lupien, B. Cantin, P.-M. Bernard, G. R. Dagenais, and J.-P. Despres
Apolipoprotein A-I and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Quebec Cardiovascular Study
Circulation, August 1, 1996; 94(3): 273 - 278.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.